What is tobacco smoke? Sociocultural dimensions of the association with Cardiovascular risk

Current Pharmaceutical Design

Volumn 16, Issue 23, 2010, Pages 2510-2517

  Leone, Aldo ^a   Landini, Linda ^b   Leone, Aurelio ^c  

^a Cometa Consortium ^*  (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c Royal Society of Health   (United Kingdom)

Author keywords

Cardiovascular risk; Heart damage; Smoking; Socio economic impact

Indexed keywords

CARBON MONOXIDE; CATECHOLAMINE; NICOTINE; THIOCYANATE;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMICAL INJURY; CORONARY ARTERY ATHEROSCLEROSIS; HEART ARRHYTHMIA; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; ISCHEMIC HEART DISEASE; PASSIVE SMOKING; PRIORITY JOURNAL; SMOKING CESSATION; SMOKING HABIT; SOCIAL CLASS; SOCIOECONOMICS; TOBACCO; TOBACCO DEPENDENCE;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS; SMOKING; SMOKING CESSATION; SOCIOECONOMIC FACTORS; TOBACCO SMOKE POLLUTION;

EID: 77955591443     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210792062948     Document Type: Article

References (94)

1. Glantz SA, Parmley WW. Passive smoking and heart disease: epidemiology, physiology, and biochemistry. Circulation 1991; 8: 247-52.
2. Leone A. Cigarette smoking and health of the heart. J Roy Soc Health 1995; 115: 354-5.
3. Wells AG. Passive smoking as a cause of heart disease. J Am Coll Cardiol 1994; 24: 546-54.
4. Glantz SA, Parmley WW. Passive smoking and heart disease. JAMA 1995; 273: 1047-53.
5. Leone A. Cardiovascular damage from smoking: a fact or belief? Int J Cardiol 1993; 38: 113-7.
6. Leone A. Relationship between cigarette smoking and other coronary risk factors in atherosclerosis: risk of cardiovascular disease and preventive measures. Curr Pharm Design 2003; 9: 2417-23.
7. Kritz H, Schmid P, Sinzinger H. Passive smoking and cardiovascular risk. Arch Intern Med 1995; 155: 1942-8.
8. Aronow WS. Effect of passive smoking on angina pectoris. N Engl J Med 1978; 299: 21-4.
9. Sandler DP, Comstock JW, Helsing KJ, Shore DL. Death from all causes in nonsmokers who lived with smokers. Am J Public Health 1989; 79: 163-7.
10. Muscat JE, Wynder EL. Exposure to environmental tobacco smoke and the risk of heart attack. Int J Epidemiol 1995; 24: 715-9.
11. Werner RM, Pearson TA. What is so passive about passive smoking? Secondhand smoke as a cause of atherosclerotic disease. JAMA 1998; 279: 157-8.
12. Kawachi I, Colditz GA, Speizer FE, et al. A prospective study of passive smoking and coronary heart disease. Circulation 1997; 95: 2374-9.
13. Davis J, Shelton L, Watanabe I, Arnold J. Passive smoking affects endothelium and platelets. Arch Intern Med 1989; 149: 386-9.
14. Leone A, Giannini D, Bellotto C, Balbarini A. Passive smoking and coronary heart disease. Curr Vasc Pharmacol 2004; 2: 175-82.
15. Deanfield J. Passive smoking and early arterial damage. Eur Heart J 1996; 17: 645-6.
16. Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke. Nearly as large as smoking. Circulation 2005; 111: 2684-98.
17. Leone A, Mori L, Bertanelli F, Fabiano P, Filippelli M. Indoor passive smoking: its effects on cardiac performance. Int J Cardiol 1991; 8: 247-52.
18. Giannini D, Leone A, DiBisceglie D, et al. The effects of acute passive smoke exposure on endothelium-dependent brachial artery dilation in healthy individuals. Angiology 2007; 58: 211-7.
19. Vane JR, Anggard EE, Botting RM. Regulatory function of the vascular endothelium. N Engl J Med 1990; 323: 27-36.
20. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
21. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6.
22. Luscher TF, Noll G. The pathogenesis of cardiovascular disease: role of the endothelium as a target and mediator. Atherosclerosis 1995; 118: S81-90.
23. Byrd JC. Environmental tobacco smoke. Medical and legal issues. Med Clin North Am 1992; 76: 377-97.
24. Center on Addiction and Substance Abuse (CASA). Cigarettes, Alcohol, Marijuana: Gateways to illicit drug use. Columbia University 1994.
25. Peto R, Lopez AD, Boreham J, Thun M, Heath C. Mortality from smoking in developed countries: 1950-2000. Oxford: Oxford University Press 1994.
26. Wald NJ, Hackshaw AK. Cigarette smoking: an epidemiological overview. Br Med Bull 1996; 52: 3-11.
27. Leone A. Biochemical markers of cardiovascular damage from tobacco smoke. Curr Pharm Design 2005; 11: 2199-208.
28. Hummel T, Hummel C, Pauli E, Kobal G. Olfactory discrimination of nicotine-enantiomers by smokers and non-smokers. Chem Senses 1992; 17: 13-21.
29. Leone A. Biochemistry of smoking compounds. In: Coronary circulation in nonsmokers and smokers. Leone A, Ed. New York: Nova Science Publishers, Inc. 2008; pp. 79-100.
30. Auerbach O, Carter HW, Garfinkel L, Hammond EC. Cigarette smoking and coronary heart disease, a macroscopic and microscopic study. Chest 1976; 70: 697-705.
31. Penn A, Chen LC, Snyder CA. Inhalation of steady-state sidestream smoke from cigarettes promotes arteriosclerotic plaque development. Circulation 1994; 90: 1363-7.
32. US Department of Health and Human Services. The health consequences of involuntary smoking. A Report of the Surgeon General. Rockville, MD: Public Health Service, Center for Disease Control. Center for Health Promotion and Education, Office on Smoking and Health. DHHS Publication, no. (CDC) 1981; 87-8398.
33. US Department of Health, Education, and Welfare. The health consequences of smoking: a Report of the Surgeon General. Cardiovascular Disease. Rockville, MD: US Department of Health and Human Services, Public Health Service Office of Smoking and Health. DHHS Publication no. (PSH) 84-50204, 1983.
34. Lough J. Cardiomyopathy produced by cigarette smoke. Ultrastructural observations in guinea pigs. Arch Pathol Lab Med 1978; 102: 377-80.
35. Gvozdjakova A, Bada V, Sany L, et al. Smoke cardiomyopathy: disturbance of oxidative processes in myocardial mitochondia. Cardiovasc Res 1984; 18: 229-32.
36. Kjeldsen K, Thomsen HK, Astrup P. Effects of carbon monoxide on myocardium. Ultrastructural changes in rabbits after moderate, chronic exposure. Circ Res 1974; 34: 339-48.
37. Leone A, Landini L, Jr, Biadi O, Balbarini A. Smoking and cardiovascular system: Cellular features of the damage. Curr Pharm Design 2008; 14: 1771-7.
38. Meinert CL, Forman S, Jacobs DR, Stamler J. Cigarette smoking as a risk factor in men with a prior history of myocardial infarction. J Chron Dis 1979; 32:415-25.
39. Health or Smoking. Follow-up Report of the Royal College of Physicians. London: Pitman Publishing 1983.
40. Koch A, Hoffmann K, Steck W, et al. Acute cardiovascular reactions after cigarette smoking. Atherosclerosis 1980; 35: 67-75.
41. Pachinger O, Hellberg KD, Bing RJ. The effect of nicotine, propranolol, phentolamine and hexamethonium on the coronary microcirculation of the cat. J Clin Pharmacol 1972; 12: 432-9.
42. Cryer PE, Haymond MV, Santiago JV, Shah SD. Norepinephrine and epinephrine release and adrenergic mediation of smokingassociated hemodynamic and metabolic events. N Engl J Med 1976; 295: 573-7.
43. Hill P, Wynder EL. Smoking and cardiovascular disease. Effect of nicotine on the serum epinephrine and corticoids. Am Heart J 1974; 87: 491-6.
44. Westfall T, Cipolloni P, Edmundowicz A. Influence of propranolol on hemodynamic changes and plasma catecholamine levels following cigarette smoking and nicotine. Proc Soc Exp Biol Med 1966; 123: 174-9.
45. White S, McRitchie R. Nasopharingeal reflexes: integrative analysis of evoked respiratory and cardiovascular effects. Aust J Exp Biol Med Sci 1973; 51: 17-31.
46. McMurray RG, Hicks LL, Thompson DL. The effects of passive inhalation of cigarette smoke on exercise performance. Eur J Appl Physiol 1985; 54: 196-200.
47. Leone A, Bertanelli F, Mori L, Fabiano P, Bertoncini G. Ventricular arrhythmias by passive smoke in patients with pre-existing myocardial infarction. J Am Coll Cardiol 1992; 3: 256A.
48. Hole DJ, Gillis CR, Chopra C, Hawthorne VM. Passive smoking and cardiorespiratory health in a general population in the West of Scotland. BMJ 1989; 299: 423-7.
49. Leone A, Bertanelli F, Mori L, Fabiano P, Battaglia A. Features of ischaemic cardiac pathology resulting from cigarette smoking. J Smoking-Relat Dis 1994; 5: 109-14.
50. Greenberg RA, Haley NJ, Ersel RA, Loda FA. Measuring the exposure of infants to tobacco smoke. N Engl J Med 1984; 310: 1075-8.
51. Strachan DP, Jarvis MJ, Feyerabend C. Passive smoking, salivary cotinine concentration and middle ear effusion in 7-year old children. BMJ 1989; 289: 1549-52.
52. Fielding JE, Phenow KJ. Health effects of involuntary smoking. N Engl J Med 1988; 319: 1452-60.
53. Jarvis MJ, Tunstall-Pedoe H, Feyerabend C, Vesey C, Saloojee Y. Comparison of tests used to distinguish smokers from nonsmokers. Am J Publ Health 1987; 77: 1435-8.
54. Benowitz NL, Jacob P. Nicotine and cotinine elimination pharmacokinetics in smokers and non-smokers. Clin Pharmacol Ther 1993; 53: 316-23.
55. Benowitz NL. Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiol Rev 1996; 18: 188-204.
56. Vogt TM, Selvin S, Widdowson G, Hulley SB. Expired air carbon monoxide and serum thiocyanate as objective measures of cigarette exposure. Am J Public Health 1977; 67: 545-9.
57. Ekemin SA, Coxon RE, Colbert DL, Landon J, Smith DS. Urinary cotinine fluoro immunoassay for smoking status screening adapted to an automated analyser. Analyst 1992; 117: 697-9.
58. Pershagen G. Smokeless tobacco. Br Med Bull 1996; 52: 50-7.
59. Leone A. Preventive measures against damage: clean air. In: Passive smoking and cardiovascular pathology: mechanisms and physiopathological basis of damage. Leone A, Ed. New York: Nova Science Publishers, Inc. 2007; pp. 185-191.
60. World Health Organization. Ottawa charter for health promotion: a WHO international conference on health promotion. World Health Organization 1986.
61. Scollo M. Target populations. In: Tobacco and Health, K Slama ed, New York and London: Plenum Press 1995; 241-6.
62. Rigotti NA, Pashos CL. Non-smoking laws in the United States. An analysis of state and city action to limit smoking in public places and workplaces. JAMA 1991; 266: 3162-7.
63. Coalition on smoking or health. State legislated actions on tobacco issues. Washington DC. 1993.
64. Laws MB, Whitman J, Browser DM, Krech L. Tobacco availability and point of sale marketing in demographically contrasting districts of Massachusetts. Tobacco Control 2002; 11: 71-3.
65. Geckova AM, Stewart R, van Dijk JP, Orasova O, Groothoff JW, Post D. Influence of socio-economic status, parents and peers on smoking behaviour of adolescents. Eur Addict Res 2005; 11: 204-9.
66. Townsend J, Roderick P, Cooper J. Cigarette smoking by socioeconomic group, sex, and age: effects of price, income, and health publicity. BMJ 1994; 309: 923-7.
67. Ball K, Turner R. Smoking and the heart: the basis for action. Lancet 1974; 2: 822-6.
68. Spohr U, Harenberg J, Walter E, et al. Smoking-induced effects on circulatory and metabolic variables with respect to plasma nicotine and COHb levels. In: Smoking and arterial disease. Greenhalgh RM, Eds. London: Pitman Medical 1981; pp. 98-106.
69. Raitakari OT, Adams MR, McCredie RJ, Griffiths KA, Celermajer DS. Arterial endothelial dysfunction related to passive smoking is potentially reversible in healthy young adults. Ann Intern Med 1999; 130: 578-81.
70. Benowitz NL, Jacob P III, Jones RT, Rosenberg J. Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther 1982; 221: 368-72.
71. Cosentino F, Luscher TF. Effects of blood pressure and glucose on endothelial function. Curr Hypertens Rep 2001; 3: 79-88.
72. Celermajer DS, Adams MR, Clarkson P, et al. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med 1996; 334: 150-4.
73. Cooke JP, Tsao RS. Is NO an endogenous antiatherogenic molecule? Arterioscler Thromb 1994; 14: 653-5.
74. Stamler J, Wentworth D, Neaton JD, for the MRFIT Cooperative Research Group. Is the relationship between serum cholesterol and risk of death from coronary heart disease continuous and graded? Findings on 356,222 primary screenes of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823-8.
75. Cornfield J. Joint dependence of risk of coronary heart disease on serum cholesterol and systolic blood pressure: A discriminant function and analysis. Fed Proc 1962; 21 (Suppl II): 58-61.
76. Gotto AM, Jr. Interactions of the major risk factors for coronary heart disease. Am J Med 1986; 80 (Suppl 2A) 48-55.
77. Criqui MH, Barret-Connor E, Holdbrook MJ, Austin M, Turner JD. Clustering of cardiovascular disease risk factors. Prevent Med 1980; 9: 525-33.
78. Carlson LA, Bottiger LE, Ahfeldt PE. Risk factors for myocardial infarction in the Stockholm Prospective Study. A 14-year followup focussing on the role of plasma triglycerides and cholesterol. Acta Med Scand 1979; 206: 351-60.
79. Kannel WB. Some lessons in cardiovascular epidemiology from Framingham. Am J Cardiol 1976; 37: 269-82.
80. Pooling project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling project. J Chronic Dis 1978; 31: 201-306.
81. Robertson TL, Kato H, Gordon T, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California. Coronary heart disease risk factors in Japan and Hawaii. Am J Cardiol 1977; 39: 244-9.
82. Celermajer DS, Sorensen KE, Georgakopoulos D. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993; 88: 2149-55.
83. Leone A, Lopez M. Role du tabac et de la contraception orale dans l'infarctus du myocarde de la femme. Description d'un cas. Pathologica 1984; 76: 493-8.
84. Leone A, Lopez M. Oral contraception, ovarian disorders and tobacco in myocardial infarction of woman. Pathologica 1986; 78: 237-42.
85. Lin SJ, Hong CY, Chang MS, Chiang BN, Chien S. Long-term nicotine exposure increases aortic endothelial cell death and enhances transendothelial macromolecular transport in rats. Arterios Thromb 1992; 12: 1305-12.
86. Powell JT. Vascular damage from smoking: disease mechanisms at the arterial wall. Vasc Med 1998; 3: 21-8.
87. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004, 43: 1731-7.
88. Folts JD, Bonebrake FC. The effects of cigarette smoke and nicotine on platelet thrombus formation in stenosed dog coronary arteries: inhibition with phentolamine. Circulation 1982; 65: 465-70.
89. Eliot RS, Baroldi G, Leone A. Necropsy studies in myocardial infarction with minimal or no coronary luminal reduction due to atherosclerosis. Circulation 1974; 49: 1127-31.
90. Gross H, Stenberg WH. Myocardial infarction without significant lesions of coronary arteries. Arch Intern Med 1939; 64: 249-67.
91. Russel MAH. Overview of research on smoking cessation. Which directions for the future? In: Tobacco and health. Slama K, Ed. New York and London: Plenum Press 1995; pp. 425-9.
92. A clinical practice guideline for treating tobacco use and dependence: A U.S. Public Health Service report. The tobacco use and dependence clinical practice guideline panel, staff, and consortium representatives. JAMA 2000; 283: 3244-54.
93. Rosenberg L, Kaufman DW, Helmrich SP, Saphiro S. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med 1985; 313: 1511-4.
94. Gordon T, Kannel WB, McGee D, Dawber TR. Death and coronary attacks in men after giving up cigarette smoking. A report from the Framingham study. Lancet 1974; 2: 1345-8.